Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jeonju
Clinical trial register · South Korea

Clinical Trials in Jeonju, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline6 AstraZeneca5 Genmab5 Chonnam National University Hospital4 Novartis Pharmaceuticals4
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Jeonju

93 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Yonsei University
Observational
600
Yongin, Daegu, Jeonju
2026-11-09
Not yet open
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637Venous Thromboembolism, Active Cancer
DrugsEdoxaban·Apixaban
Samsung Medical Center
Phase 4
2,300
Goyang-si, Busan, Goyang, Gwangmyeong, Hwasun, Jeonju, Seoul
2026-11-01
Not yet open
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840Ischemic Stroke, Transient Ischemic Attack
DrugZastaprazan
Asan Medical Center
Phase 3
984
Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul
2026-10-15
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Busan, Jeonju, Seongnam, Seongnam-si, Seoul, Suwon, Yangsan
2026-09-29
Recruiting
Yonsei University
Not applicable
748
Yongin-si, Daegu, Jeonju
2026-06-18
Recruiting
Samsung Medical Center
Observational
396
Daegu, Daejeon, Seongnam-si, Yangsan, Incheon, Jeju City, Jeonju, Hwasun
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Suwon, Jeonju, Seoul, Busan
2026-05-27
Recruiting
Transition of Care in Pediatric Rare Endocrine Disorders
NCT07786142Endocrine Disorder, Rare Disorders
Seoul National University Hospital
Not applicable
150
Daegu, Daejeon, Gwangju, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2026-05-20
Not yet open
Noseguard for Prevention of Respiratory Infections in Real-World Use
NCT07516977Respiratory Infection Virus, COVID-19, Influenza
Daewoong Pharmaceutical Co. LTD.
Not applicable
2,000
Jeonju
2026-04-20
Recruiting
LEXURE for Post-Stroke Aphasia
NCT07570264Aphasia
Nunaps Inc
Not applicable
116
Ansan, Busan, Chuncheon, Daegu, Gwangju, Ilsan, Jeonju, Seoul
2026-04-16
Recruiting
Eli Lilly and Company
Phase 2
60
Dongjak-gu, Incheon, Jeonju, Seoul
2026-04-14
Not yet open
Aribio Lab Co., Ltd.
Phase 2
135
Daegu, Seongnam-si, Yongin, Jeonju, Seoul
2026-04
Recruiting
Pfizer
Phase 2/3
1,156
Jeonju, Seoul
2026-02-11
Recruiting
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
NCT07687706Ischemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular Disease
DrugTegoprazan
Hanyang University Guri Hospital
Phase 3
1,524
Busan, Daegu, Chuncheon, Anyang-si, Iksan, Jeonju, Cheongju-si, Guri-si
2026-01-26
Recruiting
ROKIT Healthcare
Phase 4
104
Daegu, Bucheon-si, Guri-si, Gwangmyeong, Seongnam-si, Goyang, Incheon, Jeonju
2025-12-29
Not yet open
HK inno.N Corporation
Phase 1
74
Jeonju
2025-12-27
Recruiting
UCB Biopharma SRL
Phase 3
320
Anyang-si, Bucheon-si, Busan, Gwangju, Jeonju, Seongnam-si, Seoul
2025-11-14
Recruiting
GlaxoSmithKline
Phase 2
363
Busan, Incheon, Jeonju, Seoul
2025-10-30
Recruiting
Samsung Medical Center
Not applicable
3,500
Bucheon-si, Daegu, Gwangju, Gwangmyeong, Ilsan, Incheon, Jeonju, Jinju
2025-10-02
Recruiting
Sanofi
Phase 3
942
Anyang-si, Daegu, Jeonju, Seoul
2025-09-17
Recruiting
Chonnam National University Hospital
Not applicable
256
Busan, Daegu, Gwangju, Jeonju, Seoul, Ulsan
2025-08-18
Recruiting
Pusan National University Yangsan Hospital
Phase 2
186
Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2025-07-23
Recruiting
Daiichi Sankyo
Phase 2
130
Busan, Daegu, Goyang-si, Incheon, Jeonju, Seongnam, Seoul, Suwon
2025-07-18
Recruiting
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT07002164Myocardial Infarction (MI), Heart Failure
Chonnam National University Hospital
Not applicable
780
Changwon, Daegu, Daejeon, Gwangju, Jeonju, Jinju, Pusan, Seongnam
2025-07-15
Recruiting
AstraZeneca
Phase 2
987
Anyang-si, Cheongju-si, Chuncheon, Daegu, Jeonju, Seongnam-si, Seoul, Wŏnju
2025-06-27
Recruiting
GlaxoSmithKline
Phase 3
961
Daegu, Incheon, Jeonju, Seoul
2025-06-23
Recruiting
Pfizer
Phase 2
252
Jeonju, Daegu, Seoul
2025-05-20
Recruiting
Medipixel XA-Assisted PCI in Coronary Artery Disease
NCT06985693Percutaneous Coronary Intervention (PCI), Coronary Arterial Disease (CAD)
CHA University
Not applicable
830
Gwangmyeong, Seongnam-si, Daegu, Gwangju, Jeonju, Ulsan
2025-05-15
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Seongnam-si, Jeonju, Busan, Sejong, Seoul
2025-04-24
Recruiting
Samsung Medical Center
Not applicable
1,200
Ansan, Daegu, Gangneung, Goyang, Gwangju, Gwangmyeong, Incheon, Jeonju
2025-04-07
Recruiting
Pfizer
Phase 3
674
Cheonan-si, Jeonju, Seongnam, Busan, Seoul, Daegu
2025-04-01
Recruiting
AstraZeneca
Phase 3
990
Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wŏnju
2025-03-18
Recruiting
Chungnam National University Hospital
Not applicable
150
Jeonju, Daejeon
2025-03-06
Recruiting
Daiichi Sankyo
Phase 3
726
Cheongju-si, Daegu, Goyang-si, Hwasun-gun, Incheon, Jeonju, Seongnam, Seongnam-si
2025-02-27
Recruiting
GlaxoSmithKline
Phase 3
520
Hwasun, Jeonju, Seoul, Ulsan
2024-12-16
Active, closed
HanAll BioPharma Co., Ltd.
Phase 4
50
Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon
2024-12-12
Active, closed
Daiichi Sankyo
Phase 3
700
Busan, Daegu, Hwasun-gun, Incheon, Jeonju, Seongnam-si, Seoul, Suwon
2024-11-19
Active, closed
Incyte Corporation
Phase 3
349
Ansan-si, Bucheon-si, Busan, Incheon, Jeonju, Seoul
2024-10-10
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Suwon, Jeonju, Cheongju-si, Busan, Incheon, Seoul
2024-09-12
Active, closed
Amgen
Phase 3
315
Suwon, Jeonju, Cheongju-si, Seoul
2024-09-09
Active, closed
Genmab
Phase 3
379
Busan, Seongnam-si, Daegu, Jeonju, Hwasun-gun, Seoul, Ulsan
2024-08-13
Active, closed
GlaxoSmithKline
Phase 3
10,212
Seoul, Ansan, Bucheon-si Kyunggi-do 14584, Daegu, Incheon, Jeonju, Kangwon-do, Suwon Gyeonggi-do
2024-08-01
Recruiting
GlaxoSmithKline
Phase 3
150
Jeonju, Seoul
2024-07-19
Recruiting
AstraZeneca
Phase 2
80
Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon
2024-07-16
Active, closed
Exelixis
Phase 2/3
600
Busan, Suwon, Yangsan, Jeonju, Seoul
2024-06-07
Recruiting
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
NCT06227754ST Elevation Myocardial Infarction, Myocardial Infarction
Chonnam National University Hospital
Not applicable
1,500
Daegu, Gwangju, Iksan, Incheon, Jeju City, Jeonju, Jinju, Seoul
2024-03-25
Recruiting
AstraZeneca
Phase 3
5,250
Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan
2024-02-21
Active, closed
Regeneron Pharmaceuticals
Phase 3
216
Gyeonggi-do, Suwon, Yangsan, Jeonju, Incheon, Busan, Daegu, Seoul
2024-02-15
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Jeonju, Hwasun-gun
2024-01-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Suwon, Jeonju, Incheon, Busan, Daegu, Seoul, Ulsan
2023-12-28
Recruiting
LG Chem
Observational
172
Jeonju
2023-12-21
Recruiting
Double Unit Cord Blood Transplant in Hematologic Malignancies.
NCT06712108Adult Double Unit Cord Blood Transplant
Seoul National University Hospital
Observational
40
Jeonju, Daegu, Pusan, Seongnam, Seoul
2023-12-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Goyang-si, Suwon, Jeonju, Busan, Daegu, Seoul
2023-12-12
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Haeundae, Gwangju, Seoul, Gyeonggi-do, Incheon, Jeonju
2023-12-11
Recruiting
Astellas Pharma Korea, Inc.
Observational
202
Goyang-si, Suwon, Jeollanam-do, Jeonju, Busan, Daegu, Daejeon, Incheon
2023-11-01
Recruiting
AbbVie
Phase 3
1,500
Busan, Daegu, Daejeon, Seongnam-si, Incheon, Jeonju, Seoul
2023-10-11
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
Busan, Ulsan, Suwon, Jinju, Jeonju, Daegu, Sinchon-dong, Songpa-dong
2023-10-04
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Incheon, Jeonju, Hwasun, Busan, Seoul
2023-09-18
Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Advanced Technology & Communications
Not applicable
180
Incheon, Gwangmyeong, Jeonju, Gwangju, Daegu, Gyeonggi-do, Daejeon, Seoul
2023-05-15
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Active, closed
Genmab
Phase 3
900
Busan, Seongnam-si, Daegu, Jeonju, Seoul, Ulsan
2023-02-08
Active, closed
Areteia Therapeutics
Phase 3
600
Anyang-si, Bucheon-si, Busan, Gwangju, Incheon, Jeonju, Seoul, Suwon
2023-01-30
Recruiting
AstraZeneca
Phase 3
3,527
Daegu, Jeonju, Seoul
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Busan, Incheon, Jeonju, Seongnam, Seoul, Wŏnju
2022-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Busan, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seoul
2022-10-13
Active, closed
Seoul National University Bundang Hospital
Observational
1,000
Bucheon-si, Chungju, Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju
2022-09-28
Active, closed
Genmab
Phase 3
549
Busan, Seongnam-si, Daegu, Jeonju, Seoul
2022-09-20
Recruiting
GlaxoSmithKline
Phase 3
109
Gwangju, Jeonju, Kangwondo, Seoul, Suwon Kyunggi-do
2022-09-06
Active, closed
Yonsei University
Observational
260
Busan, Chuncheon, Ansan-si, Goyang-si, Yongin-si, Daegu, Yangsan, Jeonju
2022-08-31
Active, closed
Incyte Corporation
Phase 1/2
53
Suwon, Busan, Daegu, Incheon, Jeonju, Seoul, Ulsan
2022-07-19
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Jeonju, Daegu, Gyeonggi-do, Hwasun, Seoul
2022-05-22
Active, closed
Novartis Pharmaceuticals
Observational
670
Daegu, Kangwon Do, Wŏnju, Goyang-si, Guri-si, Jinju, Jeonju, Iksan Si
2022-05-09
Active, closed
Novartis Pharmaceuticals
Observational
683
Daegu, Wŏnju, Bucheon-si, Bundang Gu, Goyang-si, Yangsan, Jeonju, Suncheon
2022-05-09
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Busan, Daegu, Daejeon, Dongan, Goyang-si, Jeonju, Seongnam, Seoul
2022-01-15
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Daegu, Yangsan, Jeonju
2021-11-05
Active, closed
Idience Co., Ltd.
Phase 1/2
87
Jeonju, Busan, Seongnam, Seoul
2021-06-28
Active, closed
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis
DrugCCRT
MitoImmune Therapeutics
Phase 2
60
Suwon, Jeonju, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seoul
2021-06-21
Active, closed
Incyte Corporation
Phase 3
899
Busan, Daegu, Goyang-si, Incheon, Jeonju, Jinju, Seoul, Yangsan
2021-05-11
Active, closed
Incyte Corporation
Phase 3
654
Busan, Daegu, Daejeon, Incheon, Jeonju, Seoul
2021-04-15
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
Kyungpook National University Hospital
Phase 2
364
Daegu, Daejeon, Gwangju, Incheon, Jeonju, Seoul
2020-10-23
Active, closed
Acerta Pharma BV
Phase 3
611
Busan, Goyang-si, Jeonju, Seoul, Suwon
2020-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Goyang-si, Suwon, Jeonju, Busan, Daegu, Incheon, Seoul
2020-08-20
Recruiting
Asan Medical Center
Observational
3,000
Bucheon-si, Busan, Changwon, Chuncheon, Daegu, Daejeon, Gangneung, Jeonju
2020-02-20
Active, closed
Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)
NCT04626882Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
Chonnam National University Hospital
Not applicable
994
Bucheon-si, Changwon, Daegu, Gangneung, Gwangju, Jeonju, Jinju, Seoul
2019-12-30
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Cheongju-si, Jeonju, Namdong, Seoul, Yangsan
2019-09-17
Active, closed
Biogen
Observational
74
Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gwangju, Jeonju, Seoul
2019-07-02
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Daegu, Goyang-si, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seongnam-si, Seoul
2018-11-28
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Suwon, Daegu, Jeonju, Busan
2018-10-04
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Busan, Daegu, Goyang-si, Jeonju, Seongnam-si, Seoul
2018-06-26
Active, closed
Acerta Pharma BV
Phase 3
310
Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Tonggu
2017-02-02
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Daejeon, Gwangju, Jeonju, Seoul, Suwon, Ulsan
2016-12
Recruiting
Medtronic
Observational
20,000
Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Jeonju, Seongnam-si
1983-01
Rows per page Showing 1–93 of 93
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/jeonju

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 93 of those studies with a site in Jeonju.

How many clinical trials are recruiting in Jeonju?

49 of the 93 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 38 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jeonju), 93 studies
PhaseStudiesRecruitingShare
Phase 3432146.2%
Not applicable131114%
Observational13714%
Phase 212712.9%
Phase 1/2404.3%
Phase 2/3313.2%
Phase 4313.2%
Phase 1212.2%

Most active sponsors

Lead sponsors with the most studies (Jeonju)
Lead sponsorStudiesRecruiting
GlaxoSmithKline65
AstraZeneca55
Genmab50
Chonnam National University Hospital43
Incyte Corporation40
Novartis Pharmaceuticals41
Regeneron Pharmaceuticals43
Samsung Medical Center43
Daiichi Sankyo32
Pfizer33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.